Cargando…

Population Pharmacokinetics of Tadalafil in Pediatric Patients with Pulmonary Arterial Hypertension: A Combined Adult/Pediatric Model

BACKGROUND: Tadalafil 40 mg once daily is approved for adult patients with pulmonary arterial hypertension (PAH). To investigate and potentially fulfill an unmet need in pediatric patients with PAH, pharmacokinetic (PK) data were explored in a pediatric phase Ib/II study and pooled with prior phase...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferguson-Sells, Lisa, Velez de Mendizabal, Nieves, Li, Baohui, Small, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813705/ https://www.ncbi.nlm.nih.gov/pubmed/34379314 http://dx.doi.org/10.1007/s40262-021-01052-8

Ejemplares similares

Physiologically based pharmacokinetic modeling of tadalafil to inform pediatric dose selection in children with pulmonary arterial hypertension
por: Rehmel, Jessica, et al.
Publicado: (2021)

Pharmacokinetics and safety of tadalafil in a paediatric population with pulmonary arterial hypertension: A multiple ascending‐dose study
por: Small, David, et al.
Publicado: (2019)

Efficacy and safety of tadalafil in a pediatric population with pulmonary arterial hypertension: phase 3 randomized, double-blind placebo-controlled study
por: Ivy, Dunbar, et al.
Publicado: (2021)

Tadalafil Nanoemulsion Mists for Treatment of Pediatric Pulmonary Hypertension via Nebulization
por: Elbardisy, Bassant, et al.
Publicado: (2022)

Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension
por: Sitbon, Olivier, et al.
Publicado: (2020)

Tadalafil: the evidence for its clinical potential in the treatment of pulmonary arterial hypertension
por: Katz, Stuart D.
Publicado: (2007)

Use of Tadalafil for Treating Pulmonary Arterial Hypertension Secondary to Chronic Obstructive Pulmonary Disease
por: Kim, Hyun-Sook, et al.
Publicado: (2007)

The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension
por: Falk, Jeremy A, et al.
Publicado: (2010)

Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: an evidence-based review
por: Henrie, Adam M, et al.
Publicado: (2015)

Sildenafil in pediatric pulmonary arterial hypertension
por: Dhariwal, AK, et al.
Publicado: (2015)

Treatment of newly diagnosed sarcoid-associated pulmonary hypertension with ambrisentan and tadalafil combination therapy
por: Abston, Eric, et al.
Publicado: (2020)

Genetics and Genomics of Pediatric Pulmonary Arterial Hypertension
por: Welch, Carrie L., et al.
Publicado: (2020)

The Effect of Grapefruit Juice on the Pharmacokinetics of Tadalafil in Rats
por: Shen, Xiuwei, et al.
Publicado: (2020)

Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats
por: Mamazhakypov, Argen, et al.
Publicado: (2020)

Upfront Combination Therapy: Growing the Case to Get Ahead of Pediatric Pulmonary Arterial Hypertension
por: Steffes, Lea C., et al.
Publicado: (2022)

Parenteral Prostanoids in Pediatric Pulmonary Arterial Hypertension: Start Early, Dose High, Combine
por: Douwes, Johannes M., et al.
Publicado: (2022)

Pulmonary arterial hypertension in the USA: an epidemiological study in a large insured pediatric population
por: Li, Lin, et al.
Publicado: (2017)

Biomarkers for Pediatric Pulmonary Arterial Hypertension – A Call to Collaborate
por: Colvin, Kelley L., et al.
Publicado: (2014)

Population Pharmacokinetics and Pharmacodynamics of the Neutralizing Antibodies Bamlanivimab and Etesevimab in Patients With Mild to Moderate COVID‐19 Infection
por: Chigutsa, Emmanuel, et al.
Publicado: (2021)

Risk stratification in adult and pediatric pulmonary arterial hypertension: A systematic review
por: Lokhorst, Chantal, et al.
Publicado: (2022)

Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial
por: Coghlan, John Gerry, et al.
Publicado: (2017)

Treatment of pediatric pulmonary hypertension
por: Hawkins, Amy, et al.
Publicado: (2009)

Editorial: Pediatric Pulmonary Hypertension
por: Beghetti, Maurice, et al.
Publicado: (2015)

Echocardiography in Pediatric Pulmonary Hypertension
por: Jone, Pei-Ni, et al.
Publicado: (2014)

Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis
por: Kuwana, Masataka, et al.
Publicado: (2020)

The impact of ambrisentan and tadalafil upfront combination therapy on cardiac function in scleroderma associated pulmonary arterial hypertension patients: cardiac magnetic resonance feature tracking study
por: Sato, Takahiro, et al.
Publicado: (2017)

Magnetic resonance imaging of the right ventricle in pediatric pulmonary arterial hypertension
por: Blalock, Shannon, et al.
Publicado: (2013)

Pediatric Perioperative Pulmonary Arterial Hypertension: A Case-Based Primer
por: Shah, Shilpa, et al.
Publicado: (2017)

Intravenous treprostinil via an implantable pump in pediatric pulmonary arterial hypertension
por: Desole, Susanna, et al.
Publicado: (2018)

Oral treprostinil in transition or as add-on therapy in pediatric pulmonary arterial hypertension
por: Ivy, D. Dunbar, et al.
Publicado: (2019)

Bosentan for Treatment of Pediatric Idiopathic Pulmonary Arterial Hypertension: State-of-the-Art
por: Wang, Yuchen, et al.
Publicado: (2019)

The role of tadalafil in treated hypertensive patients with erectile dysfunction
por: Grossman, Ehud
Publicado: (2022)

Food Administration and Not Genetic Variants Causes Pharmacokinetic Variability of Tadalafil and Finasteride
por: Villapalos-García, Gonzalo, et al.
Publicado: (2023)

Correction: Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis
Publicado: (2020)

Data-driven computational models of ventricular-arterial hemodynamics in pediatric pulmonary arterial hypertension
por: Tossas-Betancourt, Christopher, et al.
Publicado: (2022)

Population pharmacokinetic analysis of sildenafil in term and preterm infants with pulmonary arterial hypertension
por: Rhee, Su-jin, et al.
Publicado: (2022)

Tadalafil for veterans with chronic obstructive pulmonary disease—pulmonary hypertension: A multicenter, placebo‐controlled randomized trial
por: Maron, Bradley A., et al.
Publicado: (2022)

Population Pharmacokinetics of Pyronaridine in Pediatric Malaria Patients
por: Ayyoub, Amal, et al.
Publicado: (2016)

Asenapine pharmacokinetics and tolerability in a pediatric population
por: Dogterom, Peter, et al.
Publicado: (2018)

2537. Population Pharmacokinetics of Isavuconazole in Pediatric Patients
por: Desai, Amit, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_70b7ve1eacrg90kkbj9pu0jk4j